- Home
- AKTX vs NTIP Comparison
AKTX vs NTIP Comparison
Compare AKTX & NTIP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- AKTX
- NTIP
- Stock Information
- Founded
- AKTX N/A
- NTIP 1990
- Country
- AKTX United States
- NTIP United States
- Employees
- AKTX N/A
- NTIP N/A
- Industry
- AKTX Biotechnology: Pharmaceutical Preparations
- NTIP Multi-Sector Companies
- Sector
- AKTX Health Care
- NTIP Miscellaneous
- Exchange
- AKTX Nasdaq
- NTIP Nasdaq
- Market Cap
- AKTX 35.7M
- NTIP 28.6M
- IPO Year
- AKTX N/A
- NTIP 1998
- Fundamental
- Price
- AKTX $1.08
- NTIP $1.27
- Analyst Decision
- AKTX
- NTIP
- Analyst Count
- AKTX 0
- NTIP 0
- Target Price
- AKTX N/A
- NTIP N/A
- AVG Volume (30 Days)
- AKTX 22.7K
- NTIP 26.5K
- Earning Date
- AKTX 08-18-2025
- NTIP 08-11-2025
- Dividend Yield
- AKTX N/A
- NTIP 7.66%
- EPS Growth
- AKTX N/A
- NTIP N/A
- EPS
- AKTX N/A
- NTIP N/A
- Revenue
- AKTX N/A
- NTIP $250,000.00
- Revenue This Year
- AKTX N/A
- NTIP N/A
- Revenue Next Year
- AKTX N/A
- NTIP N/A
- P/E Ratio
- AKTX N/A
- NTIP N/A
- Revenue Growth
- AKTX N/A
- NTIP N/A
- 52 Week Low
- AKTX $0.85
- NTIP $1.16
- 52 Week High
- AKTX $4.40
- NTIP $1.78
- Technical
- Relative Strength Index (RSI)
- AKTX 41.09
- NTIP 59.56
- Support Level
- AKTX $1.10
- NTIP $1.20
- Resistance Level
- AKTX $1.15
- NTIP $1.42
- Average True Range (ATR)
- AKTX 0.03
- NTIP 0.06
- MACD
- AKTX 0.00
- NTIP 0.01
- Stochastic Oscillator
- AKTX 10.00
- NTIP 61.54
About AKTX Akari Therapeutics plc ADS
Akari Therapeutics PLC is an oncology company developing next-generation antibody-drug conjugates (ADCs) designed around novel, proprietary cancer-killing toxins (payloads). The company believes these novel payloads may have the potential to transform the efficacy and safety outcomes of ADCs as cancer therapies beyond options that are currently available or in development. Its lead product candidate is AKTX-101, a preclinical stage Trop2-targeting ADC that combines PH1 with the Trop2 antibody, which is expressed in the highest number of solid tumor cancer types, including lung, breast, colon and prostate.
About NTIP Network-1 Technologies Inc.
Network-1 Technologies Inc is involved in the business of the development, licensing, and protection of intellectual property assets. The company's current plan includes continuing to pursue licensing opportunities for its intellectual property assets.